scholarly journals Standardization of Epidermal Growth Factor Receptor (EGFR) Measurement by Quantitative Immunofluorescence and Impact on Antibody-Based Mutation Detection in Non–Small Cell Lung Cancer

2011 ◽  
Vol 179 (2) ◽  
pp. 580-589 ◽  
Author(s):  
Anastasios Dimou ◽  
Seema Agarwal ◽  
Valsamo Anagnostou ◽  
Hollis Viray ◽  
Stephen Christensen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Mutation Detection ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Quantitative Immunofluorescence ◽  
Epidermal Growth

scholarly journals Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer

2021 ◽  
Vol 22 (5) ◽  
pp. 2625
Author(s):  
Sara Elena Rebuzzi ◽  
Lodovica Zullo ◽  
Giovanni Rossi ◽  
Massimiliano Grassi ◽  
Veronica Murianni ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Molecular Targets ◽  
Small Cell ◽  
Targeted Agents ◽  
Small Cell Lung ◽  
Epidermal Growth

In the scenario of systemic treatment for advanced non-small cell lung cancer (NSCLC) patients, one of the most relevant breakthroughs is represented by targeted therapies. Throughout the last years, inhibitors of the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), c-Ros oncogene 1 (ROS1), and V-raf murine sarcoma viral oncogene homolog B (BRAF) have been approved and are currently used in clinical practice. However, other promising molecular drivers are rapidly emerging as therapeutic targets. This review aims to cover the molecular alterations with a potential clinical impact in NSCLC, including amplifications or mutations of the mesenchymal–epithelial transition factor (MET), fusions of rearranged during transfection (RET), rearrangements of the neurotrophic tyrosine kinase (NTRK) genes, mutations of the Kirsten rat sarcoma viral oncogene (KRAS) and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA), as well as amplifications or mutations of human epidermal growth factor receptor 2 (HER2). Additionally, we summarized the current status of targeted agents under investigation for such alterations. This revision of the current literature on emerging molecular targets is needed as the evolving knowledge on novel actionable oncogenic drivers and targeted agents is expected to increase the proportion of patients who will benefit from tailored therapeutic approaches.

scholarly journals Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review

Cells ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 1206
Author(s):  
Emma-Anne Karlsen ◽  
Sam Kahler ◽  
Joan Tefay ◽  
Shannon R. Joseph ◽  
Fiona Simpson
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Targeted Therapy ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Resistance Patterns ◽  
Epidermal Growth

Globally, lung cancer is the leading cause of cancer-related death. The majority of non-small cell lung cancer (NSCLC) tumours express epidermal growth factor receptor (EGFR), which allows for precise and targeted therapy in these patients. The dysregulation of EGFR in solid epithelial cancers has two distinct mechanisms: either a kinase-activating mutation in EGFR (EGFR-mutant) and/or an overexpression of wild-type EGFR (wt-EGFR). The underlying mechanism of EGFR dysregulation influences the efficacy of anti-EGFR therapy as well as the nature of resistance patterns and secondary mutations. This review will critically analyse the mechanisms of EGFR expression in NSCLC, its relevance to currently approved targeted treatment options, and the complex nature of secondary mutations and intrinsic and acquired resistance patterns in NSCLC.

Sign in / Sign up

Export Citation Format

Share Document